ea0020p570 | Neuroendocrinology, Pituitary and Behaviour | ECE2009
Mazziotti Gherardo
, Floriani Irene
, Bonadonna Stefania
, Torri Valter
, Chanson Philippe
, Giustina Andrea
Objective: Somatostatin analogues (SSA) are widely used for the treatment of patients with neuroendocrine tumors. These drugs are able to influence glucose metabolism by an inhibitory effect of insulin secretion, but the clinical impact of this effect is uncertain. Most of the data on this topic have been obtained from studies including patients in acromegaly, one the major indication for SSA, which are limited in terms of numerosity and study duration. Therefore, we have carr...